Donati, SimoneSimoneDonatiYang, Chang-HaoChang-HaoYangXu, XunXunXuMura, MarcoMarcoMuraGiocanti-Aurégan, AudreyAudreyGiocanti-AuréganHoerauf, HansHansHoeraufAllmeier, HelmutHelmutAllmeierMachewitz, TobiasTobiasMachewitzJohnson, Kristian TKristian TJohnsonSantoro, ElinaElinaSantoroCHANG-HAO YANG et al.2024-01-182024-01-182024-012193-8245https://scholars.lib.ntu.edu.tw/handle/123456789/638614AURIGA is the largest real-world study to date to evaluate intravitreal aflibercept (IVT-AFL) in the treatment of diabetic macular edema (DME) or macular edema secondary to retinal vein occlusion in routine clinical practice. The 24-month outcomes in the DME cohort from across 11 participating countries are reported here.enAnti-vascular endothelial growth factor; Diabetes; Diabetic macular edema; Diabetic retinopathy; Intravitreal aflibercept; Observational study; Real-world evidence; Retinal disease[SDGs]SDG3[SDGs]SDG17Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema in Routine Clinical Practice: Results from the 24-Month AURIGA Observational Studyjournal article10.1007/s40123-023-00829-3379244832-s2.0-85175627172https://api.elsevier.com/content/abstract/scopus_id/85175627172